SRD5A1

Summary

Gene Symbol: SRD5A1
Description: steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)
Alias: S5AR 1, 3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 5-alpha reductase, SR type 1, steroid 5-alpha-reductase 1, steroid 5-alpha-reductase type I
Species: human

Top Publications

  1. ncbi Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity
    Jeremy W Tomlinson
    Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, U K
    Diabetes 57:2652-60. 2008
  2. ncbi Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers
    Yi Xu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4072-9. 2006
  3. ncbi Steroid 5alpha reductase mRNA type 1 is differentially regulated by androgens and glucocorticoids in the rat liver
    Mostafa K El-Awady
    Department of Biomedical Technology, National Research Center, Cairo, Egypt
    Endocr J 51:37-46. 2004
  4. ncbi Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
    Lynn N Thomas
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 63:231-9. 2005
  5. ncbi 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production
    Takashi Suzuki
    Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
    Int J Cancer 120:285-91. 2007
  6. ncbi Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates
    Tasoula Tsilchorozidou
    Departments of Endocrinology and Chemical Biochemistry, University College London Hospitals, London W1T 3AA, United Kingdom
    J Clin Endocrinol Metab 88:5907-13. 2003
  7. ncbi Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women
    Mark O Goodarzi
    Department of Ob Gyn and Center for Androgen Related Disorders, Cedars Sinai Medical Center, 8635 West Third Street, Suite 160W, Los Angeles, CA 90048, USA
    J Clin Endocrinol Metab 91:4085-91. 2006
  8. ncbi Racial differences in the androgen/androgen receptor pathway in prostate cancer
    C A Pettaway
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Natl Med Assoc 91:653-60. 1999
  9. ncbi Molecular basis of androgen insensitivity
    A O Brinkmann
    Department of Endocrinology and Reproduction, Erasmus University Medical Center Rotterdam, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Cell Endocrinol 179:105-9. 2001
  10. ncbi Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia
    Felipe Vilchis
    Department of Reproductive Biology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Del Tlalpan, Mexico, DF CP 14000, Mexico
    J Hum Genet 53:401-6. 2008

Research Grants

  1. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    JUERGEN REICHARDT; Fiscal Year: 2002
  2. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    Laurence Kedes; Fiscal Year: 2003
  3. ENDOCRINE ROLES OF STEROID 5 ALPHA REDUCTASE ISOZYMES
    David Russell; Fiscal Year: 2003
  4. Saw Palmetto Use and Risk of Prostate Cancer
    I Min Lee; Fiscal Year: 2004
  5. Formulated Phytosterols - A New Treatment For Benign Prostatic Hyperplasia
    CURTIS SPILBURG; Fiscal Year: 2006
  6. Human aldo-keto reductases and nuclear receptor action
    TREVOR PENNING; Fiscal Year: 2009
  7. Role of 5-alpha Reductase in Testosterone Actions
    Shalendar Bhasin; Fiscal Year: 2007
  8. Equol and Regulation of Prostate Growth
    Robert J Handa; Fiscal Year: 2010
  9. Equol and Regulation of Prostate Growth
    Robert Handa; Fiscal Year: 2009
  10. NEUROSTEROIDS: PHYSIOLOGICAL RELEVANCE
    Alessandro Guidotti; Fiscal Year: 1999

Detail Information

Publications149 found, 100 shown here

  1. ncbi Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity
    Jeremy W Tomlinson
    Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, U K
    Diabetes 57:2652-60. 2008
    ....
  2. ncbi Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers
    Yi Xu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4072-9. 2006
    ..e., SRD5A1 and SRD5A2)...
  3. ncbi Steroid 5alpha reductase mRNA type 1 is differentially regulated by androgens and glucocorticoids in the rat liver
    Mostafa K El-Awady
    Department of Biomedical Technology, National Research Center, Cairo, Egypt
    Endocr J 51:37-46. 2004
    ..Moreover, our findings appear to indicate that regulation of 5alphaR1 gene is primarily at the post-transcriptional level...
  4. ncbi Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
    Lynn N Thomas
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 63:231-9. 2005
    ..However, inhibition of both 5alphaR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development...
  5. ncbi 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production
    Takashi Suzuki
    Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
    Int J Cancer 120:285-91. 2007
    ..Aromatase inhibitors may be more effective in these patients, possibly due to increasing local DHT concentration with estrogen deprivation...
  6. ncbi Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates
    Tasoula Tsilchorozidou
    Departments of Endocrinology and Chemical Biochemistry, University College London Hospitals, London W1T 3AA, United Kingdom
    J Clin Endocrinol Metab 88:5907-13. 2003
    ..This dysregulation does not seem to be the primary cause of PCOS because no correlation was found between serum androgen levels or urinary excretion of androgens with measurements of either 5alpha-R or 11beta-HSD1 activities...
  7. ncbi Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women
    Mark O Goodarzi
    Department of Ob Gyn and Center for Androgen Related Disorders, Cedars Sinai Medical Center, 8635 West Third Street, Suite 160W, Los Angeles, CA 90048, USA
    J Clin Endocrinol Metab 91:4085-91. 2006
    Despite the importance of dihydrotestosterone in androgen action, polymorphisms in the genes for the two isoforms of 5alpha-reductase (SRD5A1 and SRD5A2) have not been evaluated as risk factors for polycystic ovary syndrome (PCOS).
  8. ncbi Racial differences in the androgen/androgen receptor pathway in prostate cancer
    C A Pettaway
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Natl Med Assoc 91:653-60. 1999
    ..Collectively, these data strongly suggest racial differences within the androgen/androgen receptor pathway not only exist but could be one cause of clinically observed differences in the biology of prostate cancer among racial groups...
  9. ncbi Molecular basis of androgen insensitivity
    A O Brinkmann
    Department of Endocrinology and Reproduction, Erasmus University Medical Center Rotterdam, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Cell Endocrinol 179:105-9. 2001
    ..Differential diagnosis of AIS is possible with syndromes presenting with almost similar phenotypes but with a completely different molecular cause...
  10. ncbi Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia
    Felipe Vilchis
    Department of Reproductive Biology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Del Tlalpan, Mexico, DF CP 14000, Mexico
    J Hum Genet 53:401-6. 2008
    ..This further underscores that exon 4 of SRD5A2 may be a site prone to inactivating mutations...
  11. ncbi A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2) leads to severe male pseudohermaphroditism in a Turkish family
    Mithat Bahceci
    Department of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
    Urology 66:407-10. 2005
    ..To analyze the steroid 5-alpha reductase type 2 gene (SRD5A2) in 2 siblings with severe male pseudohermaphroditism suspected to have 5-alpha reductase deficiency in a Turkish family...
  12. ncbi Undervirilization in XY newborns may hide a 5α-reductase deficiency: report of three new SRD5A2 gene mutations
    L Maimoun
    Service d Hormonologie, Hopital Lapeyronie, CHU Montpellier et UMI, Montpellier, France
    Int J Androl 33:841-7. 2010
    ..Early molecular diagnosis is indispensable for the crucial decision of the newborn's sex of rearing...
  13. ncbi A class of 4-aza-lithocholic acid-derived haptens for the generation of catalytic antibodies with steroid synthase capabilities
    J Hasserodt
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    Bioorg Med Chem 8:995-1003. 2000
    ..Surprisingly, an inhibition study showed that the isomer with the inverted configuration at the N-oxide bound more strongly to this catalytic antibody...
  14. ncbi Aromatase, steroid-5-alpha-reductase type 1 and type 2 mRNA expression in gonads and in brain of Xenopus laevis during ontogeny
    R Urbatzka
    Department of Inland Fisheries, Leibniz Institute of Freshwater Ecology and Inland Fisheries, Müggelseedamm 310, 12587 Berlin, Germany
    Gen Comp Endocrinol 153:280-8. 2007
    ..of sexual differentiation of amphibians, we determined the mRNA expression of steroid-5-alpha-reductase type1 (Srd5a1), type2 (Srd5a2) and aromatase (Aro) during ontogeny starting from the egg and ending after completion of ..
  15. ncbi The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias
    Hanh T T Thai
    Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
    J Clin Endocrinol Metab 90:6695-8. 2005
    ..Hypospadias is one of the most common malformations in man, with an incidence of 1:300 in newborn boys. No gene has been identified that causes isolated hypospadias, but the androgenic influence is important during male genital development...
  16. ncbi Isolated micropenis reveals partial androgen insensitivity syndrome confirmed by molecular analysis
    Amrit Bhangoo
    Pediatric Endocrinology Division of Maimonides Infants and Children s Hospital of Brooklyn, Children s Hospital at SUNY Downstate, Brooklyn, NY 11219, USA
    Asian J Androl 12:561-6. 2010
    ..This underlines the importance of including AR gene analysis in the evaluation of isolated micropenis with normal plasma T to ensure proper management of the patient and appropriate genetic counseling for the family...
  17. ncbi Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2)
    R Anwar
    Department of Medicine, University of Leeds
    Mol Pathol 50:51-2. 1997
    ..This mutation produces an amino acid change from glutamic acid to lysine, and may affect the ability of the enzyme to bind its co-factor...
  18. ncbi Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors
    Olivier Cussenot
    CeRePP, Tenon Hospital, Paris, France
    Eur Urol 52:1082-7. 2007
    ....
  19. ncbi Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really associated with the malformation?
    Loes F M van der Zanden
    Department of Epidemiology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    J Clin Endocrinol Metab 95:2384-90. 2010
    ..Little is known about the genes involved in hypospadias. A few genetic associations have been reported but mainly in studies of small sample size. Most of these associations have not been replicated...
  20. ncbi Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma
    Jun Luo
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 57:134-9. 2003
    ..The therapeutic influence of SRD5A2 inhibitor finasteride on prostate cancer is currently unknown. The direction and extent of changes in SRD5A2 expression in disease tissues is a relevant issue in this regard...
  21. ncbi A common polymorphism of the SRD5A2 gene and transsexualism
    Eva Katrin Bentz
    Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University Vienna, Vienna, Austria
    Reprod Sci 14:705-9. 2007
    ..6; OR, 0.61; 95% CI, 0.11-3.32). Of note, there is no gender-specific genotype distribution among controls. The SRD5A2 Val89Leu SNP is not associated with transsexualism, refuting SRD5A2 as a candidate gene of transsexualism...
  22. ncbi Secretion of pregnane compounds from follicular and luteal ovaries in rats
    T Sawada
    Department of Animal Reproduction, College of Agriculture, University of Osaka Prefecture, Japan
    Horm Metab Res 20:100-2. 1988
    ....
  23. ncbi Pharmacogenetics of human androgens and prostatic diseases
    G Novelli
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita di Roma Tor Vergata, 00133 Roma, Italy
    Pharmacogenomics 2:65-72. 2001
    ..Pharmacogenomic investigation of constitutional and somatic DNA changes in human genes predisposing to cancer may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of PCa...
  24. ncbi Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms
    Stephane Larre
    Centre de Recherche pour les Pathologies Prostatiques EA3104, France
    BJU Int 100:679-84. 2007
    ....
  25. ncbi Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency
    Z Hochberg
    Department of Pediatrics, Rambam Medical Center, Haifa, Israel
    J Clin Endocrinol Metab 81:2821-7. 1996
    ..A homozygous point mutation was identified in exon 1, leading to a thymidine for adenine substitution, predicting amino acid substitution of leucine for glutamine at position 55...
  26. ncbi Cloning and differential expression of steroid 5 alpha-reductase type 1 (Srd5a1) and type 2 (Srd5a2) from the Harderian glands of hamsters
    Luis Ramos
    Department of Reproductive Biology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    Gen Comp Endocrinol 166:388-95. 2010
    ..In this study, we isolated specific cDNAs for 5 alpha-reductase 1 (Srd5a1) and 5 alpha-reductase 2 (Srd5a2), determined their sequences and investigated their expression in the HG of both ..
  27. ncbi A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland
    N Mononen
    Laboratory of Cancer Genetics, Dept of Clinical Chemistry, Institution of Medical Technology, University of Tampere and Tampere University Hospital, P O Box 2000, Tampere, FIN 33521, Finland
    Br J Cancer 84:1344-7. 2001
    ..Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population...
  28. ncbi The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer
    Carla H van Gils
    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    Cancer Epidemiol Biomarkers Prev 12:1194-9. 2003
    ..10). In conclusion, our findings do not provide evidence for an important role of the V89L polymorphism in the etiology of breast cancer. However, in breast cancer patients, the LL genotype may be associated with unfavorable prognosis...
  29. ncbi Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
    Muhammad T Salam
    Department of Preventive Medicine, University of Southern California, Los Angeles, Los Angeles, CA 90089, USA
    Urol Oncol 23:246-53. 2005
    ..03). Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat. These results suggest that the SRD5A2 gene may play an important role in both BPH and prostate cancer...
  30. ncbi Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer
    A Scorilas
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada
    Br J Cancer 84:760-7. 2001
    ..Long-term-outcome studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility...
  31. ncbi V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
    R K Nam
    Division of Urology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Urology 57:199-204. 2001
    ..We examined whether this polymorphism predicts the presence of prostate cancer in 320 men without cancer who underwent biopsy and cancer progression in 318 men who underwent radical prostatectomy...
  32. ncbi Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development
    Sara Lindstrom
    Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
    Cancer Res 66:11077-83. 2006
    ..Carriers of five high-risk alleles in the AR, CYP17, and SRD5A2 genes are at approximately 2-fold excess risk to develop prostate cancer...
  33. ncbi Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review
    Jun Li
    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, MS K55, Atlanta, GA 30341, USA
    Am J Epidemiol 171:1-13. 2010
    ..Analysis of well-designed population-based studies with pathway-based arrays containing common genetic variants could be useful for identifying genetic factors in prostate cancer...
  34. ncbi Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer
    Bao Li Chang
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Prostate 56:37-44. 2003
    ..However, the role of SRD5A2 sequence variants in the susceptibility to hereditary prostate cancer (HPC) has not been evaluated to date...
  35. ncbi The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer
    John K Scariano
    Department of Pathology and Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    Prostate 68:1798-805. 2008
    ..The more common and rapid catalytic isoform contains a valine residue at position 89; the slower-catalytic variant contains leucine at this position...
  36. ncbi SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis
    Chunyang Wang
    Tianjin Institute of Urological Surgery, Tianjin Key Laboratory of Urology, Tianjin Medical University, Tianjin, China
    Prostate 70:170-8. 2010
    ..To precisely estimate the relationship with more statistical power, a meta-analysis was performed...
  37. ncbi Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin
    Young Kyo Seo
    Department of Molecular Biology and Biochemistry, 3244 McGaugh Hall, University of California, UC Irvine, Irvine, CA 92697 3900, USA
    Exp Cell Res 315:3133-9. 2009
    ....
  38. ncbi A common polymorphism within the steroid 5-alpha-reductase type 2 gene and timing of menopause in Caucasian women
    Ambros Huber
    Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Eur J Obstet Gynecol Reprod Biol 125:221-5. 2006
    ..We evaluated the association between a common polymorphism of the steroid 5-alpha-reductase type 2 gene (SRD5A2) involved in androgen metabolism and the timing of menopause...
  39. ncbi Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men
    Singh Rajender
    Endocrinology Division, Central Drug Research Institute, Lucknow, India
    J Androl 30:703-10. 2009
    ..Our study emphasizes that the (TA)(9) allele might confer certain PC risk but that A49T and V89L polymorphisms do not confer PC risk in South Indian men...
  40. ncbi No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned
    C Leigh Pearce
    1Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Hum Mol Genet 17:2456-61. 2008
    ..Overall, this report highlights the importance of rigorous genotyping quality control measures and replication efforts in genetic association studies...
  41. ncbi Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men
    Naomi E Allen
    Cancer Research United Kingdom Epidemiology Unit, University of Oxford, Gibson Building, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom
    Cancer Epidemiol Biomarkers Prev 12:578-81. 2003
    ..0003). Because of the rarity of this variant allele, larger studies are needed to additionally clarify the role of the A49T polymorphism in androgen metabolism...
  42. ncbi [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer]
    Ming Tong
    Institute of Urology, First Hospital, Peking University, Beijing 100034, China
    Zhonghua Wai Ke Za Zhi 42:1493-6. 2004
    ..The correlation were studied between testosterone 5-alpha-reductase II (SRD5A2) gene polymorphisms and prognosis factors...
  43. ncbi [Genetic determinants of anatomical variants of the prostate]
    H Hamadeh
    CeRePP EA3104, Universite Paris VII, Paris, France
    Prog Urol 18:214-22. 2008
    ..The authors evaluated the correlation between specific gene polymorphisms involved in androgen and oestrogen synthesis and gross (prostatic weight) and microscopic anatomy (stroma/epithelium ratio) of the prostate during ageing...
  44. ncbi Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis
    Atsuko Shibata
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Prostate 52:269-78. 2002
    ..Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer...
  45. ncbi Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
    K Wako
    Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    J Clin Pathol 61:448-54. 2008
    ..The association between the expression of androgen receptor (AR) or androgen-converting enzymes and malignant potential in prostate cancer (PCa) was examined...
  46. ncbi Timing of neutrophil activation and expression of proinflammatory markers do not support a role for neutrophils in cervical ripening in the mouse
    Brenda C Timmons
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Biol Reprod 74:236-45. 2006
    ..cell migration in cervix through comparisons between wild-type mice and steroid 5alpha-reductase type 1 null mice (Srd5a1-/-), which fail to undergo cervical ripening due to insufficient local progesterone metabolism...
  47. ncbi Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
    Kakoli Das
    Cancer Science Institute, Department of Pathology, National University Health System, National University of Singapore, 28 Medical Drive, Singapore
    Endocr Relat Cancer 17:757-70. 2010
    The biological role of steroid 5alpha-reductase isozymes (encoded by the SRD5A1 and SRD5A2 genes) and angiogenic factors that play important roles in the pathogenesis and vascularization of prostate cancer (PC) is poorly understood...
  48. ncbi Semicomprehensive analysis of the postnatal age-related changes in the mRNA expression of sex steroidogenic enzymes and sex steroid receptors in the male rat hippocampus
    Tetsuya Kimoto
    Department of Biophysics and Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo 153 8902, Japan
    Endocrinology 151:5795-806. 2010
    ..The relative expression levels of these enzymes/receptors at PD1 were Srd5a1 > Star > Ar ∼ Hsd17b4 ∼ Hsd17b1 ∼ Hsd17b7 ∼ Esr1 ∼ Srd5a2 > Hsd17b3 > Esr2 > Cyp11a1 > Cyp17a1 > Cyp19a1 ..
  49. ncbi [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia]
    J Drsata
    Farmaceutická fakulta UK, Hradec Kralove
    Cas Lek Cesk 141:630-5. 2002
    ..Inhibition of the "aromatase" complex, which catalyzes transformation of androgens to estrogens, may contribute to the complexity of phytotherapeutic effects...
  50. ncbi Effects of androgenic-anabolic steroids in athletes
    Fred Hartgens
    Department of Surgery, Outpatient Clinic Sports Medicine, University Hospital Maastricht, and Sports Medicine Center Maastricht, Maastricht, The Netherlands
    Sports Med 34:513-54. 2004
    ..AAS-induced increment of muscle tissue can be attributed to hypertrophy and the formation of new muscle fibres, in which key roles are played by satellite cell number and ultrastructure, androgen receptors and myonuclei...
  51. ncbi A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride
    P O Gisleskog
    Division of Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, England
    Clin Pharmacol Ther 64:636-47. 1998
    ....
  52. ncbi Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings
    Regina M Martin
    Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM 42, Divisão de Endocrinologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, 01065 970 São Paulo, Brasil
    J Clin Endocrinol Metab 88:3027-34. 2003
    ..Genetic linkage to the steroid 5alpha-reductase type 1 gene (SRD5A1) was ruled out in this family...
  53. ncbi Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor
    S Prahalada
    Department of Safety Assessment, Merck Research Laboratory, West Point, Pennsylvania 19486, USA
    Prostate 35:157-64. 1998
    ..Therefore, studies were designed to determine the differences in intraprostatic hormonal levels, morphology, and 5alphaR activity in different lobes of the rat prostate...
  54. ncbi Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
    Mario A Eisenberger
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Urology 63:114-9. 2004
    ..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer...
  55. ncbi In vitro androgen-induced growth and morphogenesis of the Wolffian duct within urogenital ridge
    M Tsuji
    Department of Anatomy, University of California, San Francisco 94143
    Endocrinology 128:1805-11. 1991
    ..These data suggest that T is an important hormone in the development of the upper portion of WDs, although it is not possible to exclude a role for DHT in the development of the epididymis...
  56. ncbi 5 alpha-reductase activity in the human hair follicle concentrates in the dermal papilla
    W Eicheler
    Philipp University, Department of Dermatology, Marburg, Germany
    Arch Dermatol Res 290:126-32. 1998
    ..These results indicate that the androgen response of hair follicles depends on a differentiated intrafollicular androgen metabolism and that the dermal papilla might be a primary target in this process...
  57. ncbi Finasteride delays the onset of maternal behavior in primigravid rats
    Phyllis E Mann
    Department of Biomedical Sciences, Peabody Pavilion, Tufts University, Cummings School of Veterinary Medicine, 200 Westboro Rd, N Grafton, MA 01536, USA
    Physiol Behav 88:333-8. 2006
    ..03). These results suggest that the inhibition of maternal behavior by progesterone during pregnancy is not due to its conversion to allopregnanolone...
  58. ncbi Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride
    R Montironi
    Institute of Pathological Anatomy and Histopathology, School of Medicine, University of Ancona, Ospedale Regionale, Italy
    J Clin Pathol 52:350-4. 1999
    ..Finasteride, a 5-alpha-reductase inhibitor, is used as a chemopreventive agent because it blocks the conversion of testosterone to its byproduct which promotes prostate tumour growth...
  59. ncbi Proscar (Finasteride) inhibits 5 alpha-reductase activity in the ovaries and testes of Lytechinus variegatus Lamarck (Echinodermata: Echinoidea)
    K M Wasson
    Department of Biology, University of Alabama at Birmingham 35294 1170, USA
    Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 120:425-31. 1998
    ..These data suggest that finasteride may be used to selectively and chemically ablate 5 alpha-reduced androgen synthesis in the gonads of L. variegatus...
  60. ncbi Changes in 5 alpha- and 5 beta-reductase pathways of aldosterone metabolism by dietary sodium
    J Gorsline
    Department of Pathology and Laboratory Medicine, Miriam Hospital, Providence, RI 02906
    Am J Hypertens 1:272-5. 1988
    ..These studies demonstrate that dietary Na+, a known regulator of aldosterone synthesis, may also regulate enzymes involved in aldosterone metabolism in peripheral tissues...
  61. ncbi Compound heterozygous mutations in the SRD5A2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin
    Monica Fernandez-Cancio
    Unidad Investigación Endocrinología y Nutrición Pediátricas, Hospital Vall d Hebron, Barcelona, Spain
    J Androl 25:412-6. 2004
    ..Testis morphology showed that, during early infancy, the 5-alpha-reductase enzyme deficiency may not have affected interstitial or tubular development...
  62. ncbi The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer
    Carvell T Nguyen
    Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation Cleveland, OH, USA
    Front Oncol 2:138. 2012
    ....
  63. ncbi Variation in genes encoding the neuroactive steroid synthetic enzymes 5α-reductase type 1 and 3α-reductase type 2 is associated with alcohol dependence
    Verica Milivojevic
    Graduate Program in Neuroscience, University of Connecticut Health Center, Farmington, USA
    Alcohol Clin Exp Res 35:946-52. 2011
    ....
  64. ncbi SRD5A1 genotype frequency differences in women with mild versus severe premenstrual symptoms
    Marlene Adams
    University of Delaware, School of Nursing, Newark, Delaware, USA
    Issues Ment Health Nurs 33:101-8. 2012
    ..and two genes from the gamma-aminobutyric acid (GABA) pathway: steroid-5-alpha-reductase, alpha polypeptide 1 (SRD5A1) and gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4)...
  65. ncbi BLTK1 murine Leydig cells: a novel steroidogenic model for evaluating the effects of reproductive and developmental toxicants
    Agnes L Forgacs
    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA
    Toxicol Sci 127:391-402. 2012
    ..T) and express all the necessary steroidogenic enzymes including Star, Cyp11a1, Cyp17a1, Hsd3b1, Hsd17b3, and Srd5a1. Recombinant human chorionic gonadotropin (rhCG) and forskolin (FSK) elicited concentration- and time-dependent ..
  66. ncbi Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13)
    Amy B Hart
    Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 7:e42646. 2012
    ..affect at baseline and a SNP (rs472402) in the 1(st) intron of steroid-5-alpha-reductase-α-polypeptide-1 (SRD5A1; P = 2...
  67. ncbi The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred
    S Can
    Department of Medicine, Cornell University Medical College, New York, New York 10021, USA
    J Clin Endocrinol Metab 83:560-9. 1998
    ....
  68. ncbi Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis
    Xiaohong Chen
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Chromatogr Sci 46:356-61. 2008
    ..2% to 101% and 3.4% to 7.3%, respectively. The developed method is subsequently applied to measure the steady state finasteride concentration of patients who participated in the Prostate Cancer Prevention Trial...
  69. ncbi Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors
    Eugene Bratoeff
    Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico, D F, Mexico
    Steroids 75:499-505. 2010
    ..The overall data from this study showed that steroids 5 and 7b bind to the AR and decreased of the growth of prostate and seminal vesicles. Moreover, 4 decreased also the growth of seminal vesicles...
  70. ncbi Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells
    Shicheng Liu
    Research Department, Saitama Daiichi Pharmaceutical Co, Ltd, 8 1, Minamisakae cho, Kasukabe, Saitama 344 0057, Japan
    Biochem Biophys Res Commun 368:858-64. 2008
    ..The 5alphaR1 inhibitor MK386 exhibited a more potent inhibitory effect on 5alphaR activity than finasteride (5alphaR2 inhibitor) in bDPCs...
  71. ncbi [Differential gene expressions of steroid- and catecholamine-synthesizing enzymes in adrenal gland of rats with different diseases but the same syndromes]
    Zhi qiang Pan
    School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    Zhong Xi Yi Jie He Xue Bao 8:352-7. 2010
    ....
  72. ncbi Incontinence related to management of benign prostatic hypertrophy
    Euna Han
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Geriatr Pharmacother 5:324-34. 2007
    ..The prevalence of incontinence ranges from 11% to 34% among community-dwelling men aged > or =65 years...
  73. ncbi Early onset vulvar Lichen Sclerosus in premenopausal women and oral contraceptives
    Andreas R Günthert
    University of Goettingen, Department Obstetrics and Gynaecology, Robert Koch Str 40, 37075 Goettingen, Germany
    Eur J Obstet Gynecol Reprod Biol 137:56-60. 2008
    ..During the last decade an increase of LS in young women has been suspected. Aim of this study was to evaluate data of premenopausal women with early onset LS to find potential risk factors focussing on the use of oral contraceptives...
  74. ncbi Emerging drugs for the treatment of benign prostatic obstruction
    Hashim Hashim
    Bristol Urological Institute, Southmead Hospital, Bristol, BS10 5NB, UK
    Expert Opin Emerg Drugs 15:159-74. 2010
    ..Therefore, it is important to find new medical treatments for LUTS/BPO and this review aims to identify the potential future drugs undergoing clinical trials in this field...
  75. ncbi Prominent sex steroid metabolism in human lymphocytes
    Z Zhou
    Department of Pediatrics, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Mol Cell Endocrinol 138:61-9. 1998
    ..CYP17, HSD11L (11beta-hydroxysteroid dehydrogenase I), HSD17B1 (17beta-hydroxysteroid dehydrogenase type I) and SRD5A1 (5alpha-reductase I). B-LCL, but not T and B cells, expressed CYP11B...
  76. ncbi Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene
    W Weidemann
    Department of Endocrinology and Developmental Biology, Heinrich Heine University of Dusseldorf
    Clin Endocrinol (Oxf) 45:733-9. 1996
    ....
  77. ncbi Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract
    F W George
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235 8857, USA
    Endocrinology 138:871-7. 1997
    ....
  78. ncbi A review of combination therapy in patients with benign prostatic hyperplasia
    Kevin T McVary
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611 3008, USA
    Clin Ther 29:387-98. 2007
    ..The differing mechanisms of action and areas of efficacy of these 2 drug classes make them promising candidates for combination therapy...
  79. ncbi Neonatal programming of ethylmorphine demethylase and corticosteroid 5 alpha-reductase by testosterone, dihydrotestosterone, and estradiol. Effects of an anti-estrogen, an anti-androgen, and an inhibitor of estrogen synthetase
    E F Reyes
    Department of Biological Sciences, University of Windsor, Ontario, Canada
    Drug Metab Dispos 16:93-7. 1988
    ..Thus, testosterone is oxidized to estradiol prior to imprinting, while dihydrotestosterone imprints as the parent compound. The latter may reflect a pharmacologic occupancy of the estrogen receptor by dihydrotestosterone...
  80. ncbi Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism
    S Andersson
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas 75235
    Nature 354:159-61. 1991
    ..These results verify the existence of at least two 5 alpha-reductases in man and provide insight into a fundamental hormone-mediated event in male sexual differentiation...
  81. ncbi Olanzapine counteracts stress-induced anxiety-like behavior in rats
    Federica Locchi
    Department of Pharmacology, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy
    Neurosci Lett 438:146-9. 2008
    ..This anxiolytic effect was counteracted by the co-administration with FIN. These evidences suggest that the anxiolytic effects of olanzapine might be due to possible action of olanzapine on steroid function via activation of GABA system...
  82. ncbi Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer
    H Klein
    Department of Clinical Chemistry, University of Hamburg, F R G
    Am J Clin Oncol 11:S30-6. 1988
    ..Consequently, they should be able to use at least androstenedione for production of active androgens directly in the target tissue...
  83. ncbi Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia
    Jeannette Lee
    Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Trials 6:628-36. 2009
    ..Two phytotherapies commonly used for BPH are extracts of the fruit of Serenoa repens, the Saw palmetto dwarf palm that grows in the Southeastern US, and extracts of the bark of Pygeum africanum, the African plum tree...
  84. ncbi Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease
    S S Signorelli
    Department of Internal Medicine and Systemic Disease, Medical Angiology Section, Faculty of Medicine, University of Catania, Catania, Italy
    J Endocrinol Invest 31:1092-7. 2008
    ..Steroid 5-alpha reductase isoenzymes (SRD5A1 and SRD5A2) catalyze the conversion to the bioactive potent androgen dihydrotestosterone and other reduced ..
  85. ncbi [Primary amenorrhea and XY karyotype: identifying patients in risk]
    Rafael Fabiano Machado Rosa
    Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
    Rev Bras Ginecol Obstet 30:566-72. 2008
    ..to verify the prevalence and clinical characteristics of patients with primary amenorrhea and XY karyotype, evaluated in our Service, aiming at identifying findings which could help their recognition...
  86. ncbi 5-alpha reductase inhibitors and erectile dysfunction: the connection
    Fikret Erdemir
    Tulane University Department of Urology, New Orleans, LA, USA
    J Sex Med 5:2917-24. 2008
    ..5ARI use has been associated with adverse sexual outcomes, including erectile dysfunction (ED), ejaculatory dysfunction (EjD), and decreased libido...
  87. ncbi Inhibition of rat steroid 5 alpha-reductase (isozyme 1) by suramin
    M F Taylor
    Department of Biochemistry, College of Medicine, University of Kentucky, Lexington, USA
    Steroids 60:452-6. 1995
    ..These results suggest that suramin inhibits rat steroid 5 alpha-reductase (isozyme 1) at the level of NADPH binding to the enzyme...
  88. ncbi AKR1C1 and SRD5A1 messenger RNA expression at term in the human myometrium and chorioamniotic membranes
    Richard H Lee
    Department of Obstetrics and Gynecology, Women s and Children s Hospital, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Am J Perinatol 25:577-82. 2008
    We sought to determine relative mRNA expression of AKR1C1 and SRD5A1, which respectively encode for the key progesterone metabolizing enzymes, 20alpha-hydroxysteroid dehydrogenase and 5alpha-reductase type 1, in the myometrium and ..
  89. ncbi Distribution of rat hepatic steroid 5 alpha-reductase 1 as shown by immunohistochemistry
    W Eicheler
    Philipps University Marburg, Department of Anatomy and Cell Biology, Germany
    Exp Clin Endocrinol Diabetes 103:105-12. 1995
    ..After androgen-deprivation a considerable increase in immunoreactivity was seen in male rat liver cells, indicating androgen-dependent suppression of the enzyme in male liver...
  90. ncbi Effect of injection of gonadotrophin-releasing hormone on testicular steroidogenesis in the hypogonadal (hpg) mouse
    J W Sheffield
    Department of Veterinary Basic Sciences, Royal Veterinary College, London, UK
    J Reprod Fertil 86:609-17. 1989
    ..These results show that GnRH treatment of hpg mice will induce testicular steroidogenesis.(ABSTRACT TRUNCATED AT 250 WORDS)..
  91. ncbi Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
    Johannes Hofland
    Departments of Internal Medicine, Urology, and Pathology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Cancer Res 70:1256-64. 2010
    ..Enzymes that convert androstenedione to testosterone (AKR1C3) and testosterone to dihydrotestosterone (DHT; SRD5A1) were abundantly expressed...
  92. ncbi Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention
    Elahe A Mostaghel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 91809, USA
    Cancer Res 70:1286-95. 2010
    ..Our findings suggest that AR levels may predict the chemopreventive efficacy of SRD5A inhibitors...
  93. ncbi Steroid metabolizing enzymes in pluripotential progenitor central nervous system cells: effect of differentiation and maturation
    R C Melcangi
    Department of Endocrinology, University of Milan, Italy
    Neuroscience 72:467-75. 1996
    ..These results show that undifferentiated central nervous system cells possess androgen and progestagen metabolizing enzymes which are strongly influenced by the cellular differentiation/maturation process...
  94. ncbi Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods
    Christina Wang
    General Clinical Research Center, Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, 1000 Carson Street, Torrance, CA 90509, USA
    Steroids 73:1345-52. 2008
    ..T and DHT measurements are required for assessment of patients with ambiguous genitalia, hirsutism, during 5 alpha reductase treatment of prostate disorders, and new androgen formulations...
  95. ncbi The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial
    Roelf J C Norg
    Department of General Practice, Care and Public Health Research Institute, Maastricht University, Netherlands
    Br J Gen Pract 56:938-44. 2006
    ....
  96. ncbi Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family
    A Nordenskjold
    Department of Molecular Medicine, Karolinska Hospital St Görans Hospital, Stockholm, Sweden
    J Clin Endocrinol Metab 83:3236-8. 1998
    ..The two mutations (G196S and H231R) have been described previously and reported to give rise to partially functioning enzymes, which may explain the milder phenotype and perhaps the fertility in the preset three patients...
  97. ncbi Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice
    Sara H Windahl
    Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 6:e21402. 2011
    ..There are two well established isoenzymes of 5α-reductase (type 1 and type 2), encoded by separate genes (Srd5a1 and Srd5a2)...
  98. ncbi Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors
    Eugene Bratoeff
    Department of Pharmacy, National University of Mexico City, 04510 Mexico D F, Mexico
    Curr Med Chem 12:927-43. 2005
    ..The trienones having a more coplanar structure react faster with the enzyme thus showing a higher inhibitory activity...
  99. ncbi The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function
    Michael R Pinsky
    Department of Urology, Tulane Health Sciences Center, New Orleans, LA 70112, USA
    J Sex Med 8:3066-74. 2011
    ..Numerous clinical series have reported an association between 5-alpha-reductase inhibitors (5ARIs) and sexual dysfunction, but there are limited preclinical data available...
  100. ncbi [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]
    G Bartsch
    Urol Universitätsklinik, Frauen und Kopfklinik, Anichstrasse 35, 6020 Innsbruck Osterreich
    Urologe A 41:412-24. 2002
    ..However, the circulating and intraprostatic DHT could be further reduced by a more effective dual 5-alpha-reductase inhibitor, which would be efficacious in the treatment of benign prostate hyperplasia and other DHT-related disorders...
  101. ncbi Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy
    R Hein
    Division of Cancer Epidemiology, German Cancer Research Center DKFZ, Heidelberg, Germany
    Breast Cancer Res Treat 131:653-61. 2012
    ..polymorphisms (SNPs) in the progesterone metabolizing enzymes AKR1C3 (rs7741), AKR1C4 (rs3829125, rs17134592), and SRD5A1 (rs248793, rs3736316) using a two-center population-based case-control study from Germany with 2,502 ..

Research Grants85

  1. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    JUERGEN REICHARDT; Fiscal Year: 2002
    ....
  2. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    Laurence Kedes; Fiscal Year: 2003
    ....
  3. ENDOCRINE ROLES OF STEROID 5 ALPHA REDUCTASE ISOZYMES
    David Russell; Fiscal Year: 2003
    ....
  4. Saw Palmetto Use and Risk of Prostate Cancer
    I Min Lee; Fiscal Year: 2004
    ..abstract_text> ..
  5. Formulated Phytosterols - A New Treatment For Benign Prostatic Hyperplasia
    CURTIS SPILBURG; Fiscal Year: 2006
    ..technology was used in preliminary studies to show that properly formulated plant sterols inhibit steroid 5 alpha reductase to lower DHT...
  6. Human aldo-keto reductases and nuclear receptor action
    TREVOR PENNING; Fiscal Year: 2009
    ..of all steroidogenic enzymes after cholesterol in the same prostate specimens: Scc, CYP17A1, HSD3B2, AKR1C3, SRD5A1, SRD5A2, AKR1C2, AKR1C1, HSD17B2, HSD17B6, and UGT2B15 to determine if their levels correlate with the androgen ..
  7. Role of 5-alpha Reductase in Testosterone Actions
    Shalendar Bhasin; Fiscal Year: 2007
    ..abstract_text> ..
  8. Equol and Regulation of Prostate Growth
    Robert J Handa; Fiscal Year: 2010
    ..The long-term goal of this project is to define the mechanism by which equol acts to inhibit the pathological growth of the prostate gland ..
  9. Equol and Regulation of Prostate Growth
    Robert Handa; Fiscal Year: 2009
    ..The long-term goal of this project is to define the mechanism by which equol acts to inhibit the pathological growth of the prostate gland ..
  10. NEUROSTEROIDS: PHYSIOLOGICAL RELEVANCE
    Alessandro Guidotti; Fiscal Year: 1999
    ....
  11. Axon, Testosterone and Mental Health during Adolescence
    Tomas Paus; Fiscal Year: 2010
    ....
  12. Allium Compounds in Control of Human Prostate Cancer
    JOHN PINTO; Fiscal Year: 2003
    ....
  13. Breast cancer and HRT: genetic susceptibility within th*
    Kathleen Malone; Fiscal Year: 2006
    ..SNPs) and tagSNPs in the PGR gene, and the following progesterone metabolizing genes, AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2, and the CYP3A4 gene...
  14. CHLORINATED HYDROCARBONS EFFECTS ON MAMMALIAN SYSTEMS
    David Kupfer; Fiscal Year: 2003
    ..CYP3A4 catalyzes the metabolism of the majority of drugs and is involved in drug-drug interaction. Understanding the mechanism of 3A4 activity would be useful in predicting drug interactions and drug:drug-metabolite interactions. ..
  15. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..